Bispecific trap-antibody inhibiting interleukin-6 and vascular endothelial growth factor (KSI-101): first-time results from the Phase 1b APEX Study in patients with macular edema secondary to inflammation (MESI) September 24, 2025 By daniel.h.villero@gmail.com